ORIGINAL ARTICLES  CARDIAC SECTION 

The Journal of Cardiovascular Surgery 2003 October;44(5):597-603

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Midterm experience with the Sorin Bicarbon heart valve prosthesis for rheumatic disease

Erdil N. ¹, Cetin L. ², Ates S. ², Demirkilic U. ³, Sener E. ², Tatar H. ³, Cakir B. ⁴

¹ Department of Cardiovascular Surgery, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey 2 Department of Cardiovascular Surgery, Alkan Hospital, Ankara, Turkey 3 Department of Cardiovascular Surgery, Gülhane Military Hospital, Ankara, Turkey 4 Department of Public Health, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Full text temporaneamente non disponibile on-line. Contattaci

Back­ground. In ­this ­study, we ­present a ­single ­center expe­ri­ence ­with ­Bicarbon ­bileaflet ­valve in 307 ­patients ­with rheu­matic ­heart dis­ease.
­Methods. ­Between ­August 1998 and Sep­tember 2000, 307 ­patients under­went ­heart ­valve replace­ment ­using the ­Bicarbon ­bileaflet ­valve (­Sorin Bio­medica, ­Saluggia, ­Italy) ­with an ­average age of 47.19±13.21 ­years (­range 14 to 80 ­years), con­sisting of 147 ­males and 160 ­females at ­Alkan Hos­pital, Car­di­o­vas­cular Sur­gery Depart­ment. ­Aortic ­valve replace­ment (AVR) was per­formed in 77 ­patients, ­mitral ­valve replace­ment (MVR) in 156 ­patients and ­double ­valve replace­ment (DVR) in 74 ­patients.
­Results. The ­early mor­tality ­rate was 3.3% (10/307) and ­there was no ­late mor­tality. The actu­arial sur­vival ­rate, ­including hos­pital mor­tality, was 96.74±1.01% for the ­whole ­group, 96.5±1.5% for the MVR ­group, 97.4±1.8% for the AVR ­group and 97.3±1.9% for the DVR ­group at 35 ­months. One ­patient had obstruc­tive ­valve throm­bosis ­with MVR. The 35 ­months actu­arial ­freedom ­from ­valve throm­bosis was 99.58±0.4% for the ­whole ­group. ­Four ­patients ­were reop­er­ated and the ­35 ­months actu­arial ­freedom ­from reop­er­a­tion was 98.53±0.7% for the ­whole ­group, 98.65±0.9% for the MVR ­group, 96.73±02% for the DVR ­group and 100% for the AVR ­group. No ­instances of per­i­val­vular ­leak, hemol­ysis, endo­car­ditis or embo­lism ­were ­observed ­during the ­entire ­follow-up ­period. ­Mean ­follow-up dura­tion was 16.5±7.9 ­months (­ranged 4 to 35 ­months).
Con­clu­sions. We ­have pre­sented our mid-­term ­results ­with the ­Sorin ­Bicarbon ­bileaflet ­valve in ­patients ­with rheu­matic ­heart dis­ease, ­which pro­vided ­good clin­ical per­for­mance com­bined ­with metic­u­lous ­patient ­care and ­advanced sur­gical tech­niques.